NASDAQ:LYEL Lyell Immunopharma Q4 2024 Earnings Report $9.85 0.00 (0.00%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$9.84 -0.01 (-0.10%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Lyell Immunopharma EPS ResultsActual EPS-$14.40Consensus EPS -$4.00Beat/MissMissed by -$10.40One Year Ago EPSN/ALyell Immunopharma Revenue ResultsActual Revenue$0.01 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALyell Immunopharma Announcement DetailsQuarterQ4 2024Date3/12/2025TimeBefore Market OpensConference Call DateTuesday, March 11, 2025Conference Call Time4:00PM ETUpcoming EarningsLyell Immunopharma's Q3 2026 earnings is estimated for Tuesday, November 10, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Lyell Immunopharma Earnings HeadlinesAnalysts Are Bullish on These Healthcare Stocks: Lineage Therap (LCTX), Lyell Immunopharma (LYEL)September 26 at 10:08 AM | theglobeandmail.comLyell Immunopharma (NASDAQ:LYEL) Upgraded to "Hold" at Wall Street ZenSeptember 26 at 1:31 AM | americanbankingnews.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned. | Awesomely (Ad)Financial Survey: Anika Therapeutics (NASDAQ:ANIK) versus Lyell Immunopharma (NASDAQ:LYEL)September 21, 2026 | americanbankingnews.comLyell Immunopharma To Participate in the Baird 2026 Global Healthcare ConferenceSeptember 14, 2026 | globenewswire.comLyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal CancerSeptember 10, 2026 | globenewswire.comSee More Lyell Immunopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lyell Immunopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lyell Immunopharma and other key companies, straight to your email. Email Address About Lyell ImmunopharmaLyell Immunopharma (NASDAQ:LYEL) is a clinical-stage biotechnology company focused on developing T-cell therapies for patients with cancer. The company’s research is aimed at addressing challenges that can limit the effectiveness of cellular immunotherapies, including T-cell exhaustion, inadequate persistence and difficulty penetrating solid tumors. Lyell uses its cellular reprogramming and genetic engineering technologies to develop therapeutic T cells, including chimeric antigen receptor (CAR) T-cell candidates. Its pipeline has included investigational therapies targeting ROR1, a protein expressed by certain blood cancers and solid tumors, with programs such as LYL797 and LYL119. These candidates are being evaluated in clinical studies, and their safety and effectiveness have not been established. Founded in 2018, Lyell Immunopharma is headquartered in South San Francisco, California, and conducts research and clinical development activities primarily in the United States. The company became publicly traded on the Nasdaq under the symbol LYEL in 2021. Its work is focused on advancing engineered T-cell treatments rather than marketing approved products, and its programs remain subject to regulatory review and clinical-trial outcomes.View Lyell Immunopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/252 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindCostco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem5 Scary-Good Stocks With Strong October Catalysts and Breakout PotentialDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
